Who
Brian Kenneth Roberts
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Rezolute.
In numbers
- Trades disclosed
- 35
- Buys
- 16
- Sells
- 0
- Bought
- $247K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Jun 2021
- Last trade
- 2 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jul 2026filed 7 Jul 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $15K3,062 at $4.99 | filing |
| 2 Jul 2026filed 7 Jul 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $15K3,062 at $4.99 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $34K11,439 at $2.99 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $34K11,439 at $2.99 | filing |
| 16 Dec 2025filed 17 Dec 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $48K28,000 at $1.70 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Other | —72,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —123,000 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $11K2,500 at $4.38 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 16 Feb 2025filed 19 Feb 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 16 Feb 2025filed 19 Feb 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 14 Jun 2024filed 14 Jun 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $16K4,000 at $3.91 | filing |
| 14 Jun 2024filed 14 Jun 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $1,188300 at $3.96 | filing |
| 14 Jun 2024filed 14 Jun 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $12K3,000 at $3.91 | filing |
| 14 Jun 2024filed 14 Jun 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $1,191300 at $3.97 | filing |
| 23 May 2024filed 28 May 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $4,0801,500 at $2.72 | filing |
| 23 May 2024filed 28 May 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $16K6,000 at $2.68 | filing |
| 28 Mar 2024filed 29 Mar 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $1,275500 at $2.55 | filing |
| 14 Mar 2024filed 18 Mar 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $19K10,000 at $1.88 | filing |
News
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismRZLT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Brian Kenneth Roberts; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.